Expression of Fibroblast Growth Factor Receptor Type 2 in Primary and Recurrent Ameloblastoma Are Correlated with Ameloblastoma Clinic Characteristics

Y. Tang,T. Ji

DOI: https://doi.org/10.1016/j.ijom.2017.02.1061

2017-01-01

Abstract:Background: Fibroblast growth factor receptor type 2 (FGFR2), a receptor tyrosine kinase, is involved in a number of cell signalling pathways that contribute to cell growth and differentiation. Whether it presence in primary ameloblastoma and recurrent ameloblastoma has not been previously investigated. Objectives: This study was undertaken to detect the immunohistochemical expression of the FGFR2 in primary ameloblastoma and recurrent ameloblastoma, and to determine if it was involved in the development of ameloblastoma, especially in the invasion and recurrence of ameloblastoma. Methods: In this study, 96 formalin-fixed, paraffin-embedded tissue blocks of ameloblastoma specimens which come from patients with two surgery and patients with only one surgery were compared at protein expression level using immunohistochemistry for FGFR2 staining. Finding: The results indicated that, FGFR2 immunostaining was evident in all groups of the specimens, the staining in recurrence ameloblastoma was stronger than in primary ameloblastoma. Statistical analysis showed that FGFR2 expression levels were significantly higher in recurrence ameloblastoma than in primary ameloblastoma, and the patient with tumour size over 3 cm had a higher rate of recurrence. Conclusion: Our study suggests that the high expression rate of FGFR2 plays an important role in the invasion and recurrence of ameloblastoma.